GlassScriptPhysician profile
Shiven B Patel
NPI 1023276490
$222,941.18
in general payments reported to CMS, 2019-2025
32 companies · $75K in 2025
The $75K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.91 · 2020: $8,850 · 2021: $8,705 · 2022: $21K · 2023: $55K · 2024: $55K · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125K · Consulting Fee: $36K · Travel and Lodging: $20K · Food and Beverage: $2,471 · Honoraria: $200 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,264.15 |
| Consulting Fee | $35,727.92 |
| Travel and Lodging | $20,217.19 |
| Food and Beverage | $2,470.65 |
| Honoraria | $200.00 |
| Education | $193.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $67,142.41 | 2022-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $38,673.47 | 2023-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $34,111.40 | 2022-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $26,674.46 | 2020-2024 | Tagrisso, Imfinzi, Truqap |
| Amgen INC. | $22,889.57 | 2023-2025 | Imdelltra (Amg757), Lumakras |
| Blueprint Medicines Corporation | $4,750.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,202.50 | 2020-2025 | |
| Regeneron Pharmaceuticals, INC. | $3,733.50 | 2021 | |
| Abbvie INC. | $3,300.00 | 2025 | |
| Genzyme Corporation | $2,932.61 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,920.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $2,450.00 | 2023 | |
| Pfizer INC. | $2,435.59 | 2019-2023 | |
| Lantheus Medical Imaging, INC. | $997.50 | 2024 | |
| Beigene, LTD. | $981.67 | 2024 | Brukinsa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $754.06 | 2022-2025 | |
| Dr.Reddy'S Laboratories,INC. | $750.00 | 2025 | |
| Daiichi Sankyo INC. | $750.00 | 2022-2023 | |
| Cipla USA INC. | $750.00 | 2025 | |
| Immunocore Limited | $500.00 | 2025 | |
| Tersera Therapeutics LLC | $386.00 | 2025 | Margenza |
| Nuvation Bio INC. | $285.62 | 2025 | Ibtrozi |
| Sobi, INC | $200.00 | 2024 | |
| Incyte Corporation | $184.94 | 2022-2023 | |
| Ethicon INC. | $110.58 | 2023 | Monarch Platform |
| Glaxosmithkline, LLC. | $34.58 | 2024 | Shingrix |
| Tempus Ai, INC | $27.54 | 2024 | Xt Cdx |
| Genentech USA, INC. | $13.18 | 2023 | Tecentriq |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiven Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.